What Acupath’s ArteraAI Prostate Test rollout reveals about the next phase of precision oncology
Acupath adds ArteraAI Prostate Test to its pathology workflow. Find out what it means for AI prostate cancer risk stratification today.
Why Hologic’s Breast Cancer Index data matter for precision oncology beyond recurrence risk
Hologic’s Breast Cancer Index is changing endocrine therapy decisions. The bigger test is adoption in real-world breast cancer care.
Veracyte’s TrueMRD Medicare win pushes whole-genome MRD testing into bladder cancer surveillance
MRD testing is moving from research to reimbursement. Veracyte now has Medicare coverage, but adoption in bladder cancer care is the harder test.
Why Veracyte’s Medicare win for TrueMRD could reshape bladder cancer recurrence monitoring
MRD testing has payer momentum, but clinical adoption is tougher. Veracyte’s TrueMRD Medicare win puts bladder cancer monitoring in focus.
Valar Labs FDA breakthrough nod signals new test for AI-led bladder cancer risk prediction
Bladder cancer risk tools leave gray zones. Valar Labs’ FDA breakthrough nod tests whether AI pathology can narrow them.
Can ArteraAI Breast turn routine pathology slides into breast cancer risk intelligence?
AI can read pathology slides, but can it change breast cancer treatment decisions? ArteraAI Breast puts that question before clinicians and payers.
What Roche’s $1.05bn PathAI move reveals about the future of pathology labs
Roche wants AI pathology at scale. PathAI gives it the tissue-analysis layer needed to tighten diagnostics, trials, and precision oncology.
Plus Therapeutics reimbursement push gains traction as AMA grants CNSide a dedicated PLA code
Plus Therapeutics has won an AMA PLA code for CNSide. Read why this reimbursement milestone could shape adoption, coverage, and diagnostic growth.
Can Junction’s GRAIL tie-up do what clinical data alone could not for Galleri adoption?
Junction and GRAIL are expanding Galleri access, but can workflow integration overcome regulatory, reimbursement, and adoption hurdles? Read more.
Radiopharm Theranostics builds clinical momentum with RAD 101 data that could influence neuro-oncology workflows
Radiopharm Theranostics reports strong RAD 101 interim data in brain metastases imaging. Read expert analysis on clinical impact and regulatory outlook.